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Background: Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) symptoms often overlap. In
some IBS cases there are subtle inflammatory changes similar to the immune-mediated pathophysiology of IBD,
and the risk of both increases after infectious gastroenteritis (IGE).
Methods: To evaluate the effect of IBS and IGE on IBD risk utilizing US Department of Defense medical encounter
data, active duty personnel with IBS were matched to subjects without IBS. Medical encounter history was analyzed
to assess for incident IBD. IGE was identified from documented medical encounters and by self-report. Relative risks
were calculated using Poisson regression models.
Results: We identified 9,341 incident IBS cases and 18,678 matched non-IBS subjects and found an 8.6-fold higher
incidence (p< 0.0001) of IBD among those with IBS (238.1 per 100,000 person-years) compared to our referent
population (27.8 per 100,000 person-years). In a subset (n = 2,205) of well-defined IBS cases, IBD risk was 15 times
that of subjects without IBS. The median time between IBS and IBD diagnoses was 2.1 years. IGE also increased IBD
risk approximately 2-fold (p< 0.05) after controlling for IBS.
Conclusions: These data reflect a complex interaction between illness presentation and diagnosis of IBS and IBD
and suggest intercurrent IGE may increase IBD risk in IBS patients. Additional studies are needed to determine
whether IBS lies on the causal pathway for IBD or whether the two are on a pathophysiological spectrum of the
same clinical illness. These data suggest consideration of risk reduction interventions for IGE among IBS patients at
high disease risk.
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Functional gastrointestinal disorders (FGD) are common
and cause considerable morbidity. One of the most com-
mon FGD, irritable bowel syndrome (IBS), affects approxi-
mately 12% of the global population and results in over
$30 billion in direct and indirect medical costs annually in
the US [1-3]. A less common, yet more severe group of
disorders that shares many of the clinical symptoms of IBS
are inflammatory bowel diseases (IBD), often requiring im-
munosuppression or surgery to control symptoms and
morbid disease processes. Despite differences in clinical* Correspondence: mark.riddle@med.navy.mil
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reproduction in any medium, provided the ormorbidity and pathophysiology, given the considerable
overlap of symptoms, some have argued that IBS and IBD
may represent clinical manifestations of a pathophysiologic
spectrum of disease [4]. The hypothesis is that subclinical
inflammation and immune activation resulting from long-
term IBS precede the expression of IBD. Two relatively
large population-based studies have shown a significant
increase (5–10 fold) in the risk of IBD among those
with IBS compared to those with no prior IBS history,
with some indication that the effect may be greater for
Crohn’s disease [5,6]. However, similarities in symptom
presentation between the two conditions could lead
to misdiagnoses of less severe IBD and confound this
observation [7,8].
Recent research also points to a potential increased
IBD risk following acute infectious gastroenteritis (IGE).td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
Figure 1 Flow diagram of study population. IBS: irritable bowel syndrome; IBD: inflammatory bowel disease; CD: Crohn’s disease; UC:
ulcerative colitis; IC: indeterminate colitis. * Well-defined IBS: initial IBS diagnosis, a subsequent medical encounter (≤12 months) with
sigmoidoscopy and/or diagnostic colonoscopy and a subsequent medical encounter (≤ 12 months) with an additional ICD-9 code of IBS with no
IBD medical encounters.
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fold (95% CI, 1.7–3.3) increased risk of IBD compared to
subjects with no IGE, with the highest risk in the first
year after the IGE episode [5],. In an additional study we
found prior IGE significantly increased the risk of IBD
(OR 1.53, 95% CI 1.4–1.7) after controlling for import-
ant covariates including prior IBS diagnosis [6]. More re-
cent studies have found increased IBD risk after
Campylobacter or Salmonella infections [9,10].
Due to the well-described association between IGE
and IBS [11,12] and the potential association between
IGE, IBS, and IBD, we conducted a retrospective cohort
study on a healthy population with open access to health
care and electronic medical record data to evaluate
the differential risk of IBD among those with and with-
out IBS, the risk of IGE in subjects with IBS, and the
effect of an intercurrent IGE episode on subsequent
IBD risk.
Methods
This was a retrospective cohort study utilizing subjects
identified from the Defense Medical Surveillance System
(DMSS) from 1998 – 2008. Medical data were obtained
from ambulatory and inpatient claims data for care
obtained within the Military Health Services and the Tri-
Service Reportable Events System databases. Demographic
information was obtained from personnel records and de-
ployment data were derived from deployment rosters and
post-deployment health assessments. Selection of subjects
was limited to Active Duty personnel.
The primary risk factor was new-onset IBS identified by
the first medical encounter in which an ICD-9 code of
564.1 was given (in any diagnostic position). IBS was strati-
fied into two sub-categories, “IBS” and “well-defined IBS”.For “IBS”, subjects had a minimum of two separate medical
encounters with an ICD-9 code of IBS recorded. For “well-
defined IBS”, subjects had an initial medical encounter
with an IBS diagnosis, a concurrent and/or subsequent
medical encounter (no greater than 12 months) in which
there was a endoscopic procedural code to include diag-
nostic sigmoidoscopy and/or diagnostic colonoscopy and a
subsequent medical encounter (no greater than 12 months)
with an additional ICD-9 code of IBS and no intercurrent
diagnoses of IBD. Matched non-IBS subjects were ran-
domly selected from persons with unrelated acute or
chronic diseases within 1 year of the identified IBS subject
at the same military treatment facility (MTF) and in the
same clinical setting (inpatient/outpatient). Subjects meet-
ing the IBD diagnosis within 1 year of entrance into the
observational period were excluded to minimize potential
IBS disease misclassification.
The primary outcome was IBD, categorized into two
disease phenotypes: ulcerative colitis (UC) and Crohn’s
disease (CD). IBD subjects were classified as someone
with an ICD-9 code of 555.0, 555.1, 555.9, and 556 (all
subgroup codes). Analyses evaluated UC and CD to-
gether and separately. A diagnosis of pseudopolyposis
colon (556.4) was also included in the overall IBD ana-
lyses, but not included in the analyses of UC and CD
separately as it can be typified as either disease sub-type.
Subjects must have been diagnosed with the same condi-
tion on two separate medical encounters to be counted
as having that outcome. Subjects meeting both case defi-
nitions (CD and UC) were classified as indeterminate
colitis and were included in analyses of CD and UC.
Incidence rates were calculated using the number of
incident IBD cases and total observed person time and
were adjusted to a standard reference (per 100,000 years).
Table 1 Characteristics of cohort
Variables Well-defined IBS cohort Other IBS cohort Non-IBS cohort
N 2,205 7,136 18,678
Mean (SD) age[1] 31.2 (7.8) 30.1 (8.0) 28.5 (7.9)
N (%) male 1281 (58.1) 3996 (56.0) 15014 (80.4)[2]
Race [N (%)]
Black 394 (17.9) 1238 (17.4) 3397 (18.2)
White 1492 (67.7) 4792 (67.2) 11894 (63.7)
Other 319 (14.5) 1106 (15.5) 3387 (18.1)
Education level [N (%)][1]
High school 1348 (61.1) 4514 (63.3) 12721 (68.1)
At least some college 568 (25.8) 1771 (24.8) 3772 (20.2)
Masters or doctorate 186 (8.4) 505 (7.1) 1182(6.3)
Unknown 103 (4.7) 346 (4.9) 1003 (5.4)
Service [N (%)][1]
Army 736 (33.4) 2328 (32.6) 6137 (32.9)
Air Force 783 (35.5) 2476 (34.7) 6080 (32.6)
Navy 510 (23.1) 1649 (23.1) 4300 (23.0)
Marines 124 (5.6) 467 (6.5) 1573 (8.4)
Coast Guard 52 (2.4) 216 (3.0) 588 (3.2)
Rank [N (%)][1]
Enlisted 1813 (82.2) 5935 (83.2) 15704 (84.1)
Officer/Warrant officer 392 (17.8) 1201 (16.8) 2974 (15.9)
Marital status [N (%)][1]
Married 1358 (61.6) 4153 (58.2) 9740 (52.2)
Single 668 (30.3) 2514 (35.2) 8228 (44.1)
Other 174 (7.9) 461 (6.5) 680 (3.6)
Unknown 4 (0.2) 8 (0.1) 30 (0.2)
N (%) deployed during surveillance period 554 (25.1) 1878 (26.3) 2432 (26.0)
Primary outcomes
N (%) with IBD 22 (1.0) 53 (0.7) 19 (0.1)
N (%) with UC 11 (0.5) 22 (0.3) 11 (0.06)
N (%) with CD 9 (0.4) 24 (0.3) 5 (0.03)
N (%) with IC 2 (0.09) 6 (0.08) 3 (0.02)
Mean (SD) years of follow-up 3.6 (2.7) 3.3 (2.7) 3.7 (2.8)
[1] At start of follow-up period.
[2] 2 subjects with missing data.
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also calculated using a Poisson distribution. Subjects
were censored at the time of leaving active duty service
or at the first medical encounter in which a subsequently
confirmed IBD diagnosis was recorded.
The primary covariate evaluated was IGE, determined
by ICD-9 codes for bacterial and viral pathogens accord-
ing to four main diagnostic groupings: pathogen specific,
pathogen not specified, protozoan and viral codes. Other
covariates evaluated included age, sex, military rank,
educational status, marital status, branch of service,
place of deployments, and duration of deployments.Poisson regression models were developed using a
backwards elimination approach to evaluate the relation-
ship between IBS and IBD. Only variables significant at
an alpha= 0.20 were retained in the final models. The
model developed from all IBD was applied to each IBD
phenotype. Similar methodology was used to assess the
relative risk of IGE following a diagnosis of IBS. Statis-
tical analyses were performed using SAS v. 8.2 for Win-
dows (SAS Institute, Cary, NC). Two-tailed statistical
significance was evaluated using an alpha of 0.05.
The study protocol was approved by the Naval Medical
Research Center Institutional Review Board in compliance
Table 2 Incidence and crude and adjusted rate ratios of inflammatory bowel disease in a retrospective cohort study of active duty US military personnel
from 1998 to 2008
All IBD CD UC
Incidence* cRR (95% CI) aRR (95% CI) Incidence* cRR (95% CI) aRR (95% CI) Incidence* cRR (95% CI) aRR (95% CI)
Female 81.5 1.0 1.0 23.3 1.0 1.0 46.6 1.0 1.0
Male 98.5 1.21 (0.74, 1.96) 2.21 (1.35, 3.62) 43.2 1.85 (0.78, 4.44) 3.55 (1.47, 8.54) 43.2 0.93 (0.48, 1.80) 1.66 (0.84, 3.28)
≤1 IGE 89.4 1.0 1.0 40.1 1.0 1.0 37.0 1.0 1.0
>1 IGE 274.7 3.07 (1.42, 6.64) 2.19 (1.01, 4.75) 196.2 4.90 (1.93, 12.42) 1.51 (0.36, 6.32) 78.5 2.12 (0.51, 8.81) 3.49 (1.36, 8.95)
Not deployed 104.3 1.0 1.0 40.5 1.0 1.0 49.8 1.0 1.0
Deployed 29.6 0.28 (0.10, 0.77) 0.33 (0.12, 0.91) 22.2 0.55 (0.17, 1.78) 0.65 (0.20, 2.13) 7.4 0.15 (0.02, 1.08) 0.17 (0.02, 1.27)
No IBS 27.8 1.0 1.0 7.3 1.0 1.0 16.1 1.0 1.0
IBS 238.1 8.56 (5.18, 14.17) 9.40 (5.64, 15.6) 104.7 14.32 (5.59, 36.67) 17.30 (6.71, 44.62) 104.7 6.51 (3.29, 12.88) 6.53 (3.25, 13.11)
* Per 100,000 person-years.


















Figure 2 Number of incident IBD cases over time in active duty US military personnel.
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tection of human subjects.
Results
A total of 9,341 IBS patients were included in the study
and followed for incident IBD (Figure 1). Of those,
42.2% (n = 3,941) underwent a colonoscopy during the
surveillance period with a median time of 51 (IQR: 14,
200) days between the first IBS diagnosis and initial col-
onoscopy. Just over 55% (n = 2,205) of those IBS patients
had a subsequent IBS-related medical encounter within
1 year of the colonoscopy (without meeting the IBD case
definition) and subsequently met the well-defined IBS
definition. A total of 18,678 non-IBS subjects were
included in the referent cohort. The non-IBS subjectsTable 3 Relative incidence and risk of infectious gastroenterit
diagnosis
IBS cohort
Number of episodes Incidence*
All IGE 1088 49.1
Bacterial IGE 600 19.0
Viral IGE 915 29.0
Protozoal IGE 23 1.0
*Incidence per 1,000 person years.were identified from 200 ICD-9 codes and included sub-
jects with arthropathies and related disorders (ICD-9:
719; n = 1,760; 9.4%), unspecified disorders of the back
(ICD-9: 724; n = 4,985; 26.7%), hypertension (ICD-9: 401;
n = 1,756; 9.4%) and disorders of refraction and accom-
modation (ICD-9: 367; n = 2,891; 15.5%). The average
age of subjects with IBS was 30.4 (standard deviation
{SD}: 8.0) slightly older than the non-IBS referent cohort
(mean age: 28.5; SD: 7.9; p< 0.001). In general, the
demographics of the study population were representa-
tive of the active duty military population in terms of
race, education, branch of service, rank and marital sta-
tus (Table 1). However, females were more commonly
represented in the IBS cohorts than in the non-IBS co-
hort (43.5% and 19.6%, respectively; p< 0.001). Theis-associated medical encounters by antecedent IBS
Non-IBS cohort RR (95% CI)
Number of episodes Incidence*
1083 20.2 2.4 (2.3, 2.6)
449 6.6 2.9 (2.6, 3.3)
925 13.5 2.1 (2.0, 2.4)
9 0.1 7.7 (3.7, 16.2)
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ing 99,846 person-years of observation.
For those with IBD (n = 94), a diagnosis of UC was
slightly more common than CD (58.5% and 52.1%, re-
spectively) and 11 (11.7%) cases received multiple diag-
noses of both IBD subtypes. The incidence of IBD was
94.1 per 100,000 person-years (95% CI: 76.9, 115.2).
However, this rate was approximately 8-fold higher in
those with a prior IBS diagnosis than in those with no
prior IBS, 238.1 per 100,000 person-years (95% CI:
189.8, 298.5) and 27.8 per 100,000 person-years (95% CI:
17.7, 43.6), respectively (p< 0.0001). Limiting the ana-
lysis to those with well-defined IBS, the IBD incidence
rate increased to 279.2 cases per 100,000 person-years
(95% CI: 183.9, 424.1). In a multivariate analysis
(Table 2), the increased risk for IBD among those with
antecedent IBS compared to those with no prior IBS
remained (RR: 9.42; 95% CI: 5.65, 15.70). Male gender
(RR: 2.16; 95% CI: 1.32, 3.52) and intercedent IGE med-
ical encounters during the surveillance period (RR: 2.19;
95% CI: 1.01, 4.75) were also independently associated
with increased IBD risk. In contrast, deployment during
the surveillance period was associated with a decreased
risk of IBD (RR: 0.34; 95% CI: 0.12, 0.92).
Estimates of CD and UC incidence were quite similar
(38.1 and 44.1 per 100,000 person-years, respectively).
When analyzing IBD subtypes in the same model estab-
lished for all IBD, the relative risk of CD among those
with IBS compared to those without IBS was approxi-
mately twice the UC relative risk {14.32 (95% CI: 5.59,
36.67) and 6.51 (95% CI: 3.29, 12.88), respectively}, al-
though not statistically different. Similarly, when limiting
analyses to the well-defined IBS cohort, the relative risk
of CD was 1.6-fold higher in those with IBS compared
to those without (CD: 18.4; p= 0.006; UC: 11.2;
p= 0.002). No other rate ratio estimates were signifi-
cantly different when the non-IBS cohort was stratified
by acute or chronic illnesses matching (data not shown).
Incident IBD diagnoses by antecedent IBS diagnosis
are shown in Figure 2. For subjects with IBS who were
subsequently diagnosed with IBD, the median time to
the first IBD diagnosis was 2.1 years (IQR: 1.4, 3.8).
There was no significant difference (p= 0.5) in the time
to reaching an IBD outcome for subjects with UC (me-
dian: 2.1 years; IQR: 1.4, 4.4) or CD (median: 1.8 years;
IQR: 1.4, 3.3). While the time to meeting the IBD out-
come definition was more prolonged for subjects without
an antecedent IBS diagnosis (median: 2.6; IQR: 1.9, 4.5),
this difference was not statistically significant (p=0.2). Of
the subjects with antecedent IBS who ultimately met the
IBD definition, 28 (37.3%) continued to be coded for IBS
for a median 278 (IQR: 66, 698) days after IBD diagnosis.
IGE during the follow-up period was associated with
an increased risk of IBD after controlling for IBS,deployment and gender (Table 2). Additionally, during
the follow-up period the incidence of medical encoun-
ters for IGE in the IBS cohort was 2.4-fold that of the
non-IBS cohort (p< 0.001) (Table 3). This effect was ap-
parent for all IGE infection diagnosis groups (e.g. bacter-
ial, viral, and protozoal). Limiting analyses to a subset of
subjects who were deployed to Iraq or Afghanistan in
2008, compared to subjects with no IBS, those with IBS
were almost 3 times as likely (RR: 2.7; 95% CI: 1.8, 4.0)
to self-report a diarrheal episode that prevented the sub-
ject from performing their duties (p< 0.001). Among
those with IBS who reported diarrhea during deploy-
ment 39.6% reported ongoing diarrheal symptoms after
the deployment. This was significantly higher (p< 0.001)
than in subjects with IBS who did not self-report diar-
rhea during deployment (7.1%). Similarly, among sub-
jects without diagnosed IBS, those reporting an acute
diarrheal episode during deployment were more likely
(p< 0.001) to report ongoing diarrheal symptoms after
deployment (11.5%) than were those with no reported
acute diarrhea episode during deployment (2.7%).Discussion
We found the incidence of IBD in the cohort of persons
with a prior diagnosis of IBS was approximately 9 times
higher than in the referent cohort (non-IBS). Similarly,
Garcia-Rodriguez et al. found a 16.3-fold increased risk
of IBD in a cohort of patients with IBS, compared to the
general population, an association that was more pro-
nounced for CD than UC [5]. Using a case–control
design, we previously reported on this association in a
comparable population, albeit at a lower magnitude than
reported by Garcia-Rodriguez et al. [6]. This retrospect-
ive cohort study builds on these two initial reports using
a more well-defined study population and detailed evalu-
ation of medical encounters for IBS and non-IBS subjects.
Additionally, we found that the rate ratio associated with
IBS was higher for CD than UC, also consistent with the
prior studies.
The association between IBS and IBD is well-
recognized; however, the mechanism(s) underlying this
association is a source of ongoing research. Some have
argued that IBS and IBD represent clinical presentations
on a pathophysiologic spectrum of disease given the
considerable overlap between symptoms in patients with
IBS and IBD, whereby IBS symptoms represent sub-
clinical inflammation and immune activation that pro-
gress in severity towards the expression of IBD [4,13].
Increased mucosal barrier defects in some patients with IBS
may also contribute to the increase passage of luminal anti-
gens of dietary and bacterial origin into the sub-mucosal
which may result in the further activation of mucosal
immune responses involved in the genesis of IBD [14].
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the independent associations with antecedent Campylo-
bacter jejuni infection which have been described
[9,10,15-17]. C. jejuni, a leading cause of enterocolitis
worldwide, has been shown to permit the translocation
of normal, noninvasive microflora via novel processes
that implicate epithelial lipid rafts and M-cell transport
and induce a proinflammatory response [18-20]. This
disruption in intestinal barrier function may prime the
intestine for chronic inflammatory responses in suscep-
tible individuals. Follow-on genetic studies of the Walk-
erton, Ontario STEC-Campylobacter outbreak found
that subjects with single nucleotide polymorphisms for
genes encoding proteins involved in epithelial cell bar-
rier function and the innate immune response to enteric
bacteria (TLR9, IL6, and CDH1) were independently
associated with development of IBS following acute
gastroenteritis [21]. Interestingly, recent experimental
and clinical evidence implicate aberrant CDH1 function
related to maintenance of epithelial barrier integrity with
increased risk of IBD as well [22,23]. Furthermore, Chae
et al. reported that genotype and allelic frequencies
(among four single nucletide polymorphisms) of
TNFRSF17, a gene expressed in mature B cells and
thought to be important for B cell development and
autoimmune response, were similar in IBS and UC
patients compared to controls [24]. Finally, recent find-
ings have suggested that there may be similarities in
serotonin signaling between IBS and UC patients that
could explain the altered motility, secretion, and sensa-
tion common to both [25]. Clearly, more studies are
needed to evaluate the potential overlap in pathogenesis
between these two disorders in terms of genetic, host
and environmental interactions which may support the
observed epidemiological findings.
Another potential explanation for the observed associ-
ation may be the symptom overlap between IBS and IBD
patients and possible misdiagnoses of IBS in patients
with IBD. In an effort to minimize this effect, we ana-
lyzed a subset of our IBS cohort that had a colonoscopy
without an IBD diagnosis while receiving IBS-related
medical care. In this subset analysis, IBD incidence
remained significantly elevated compared to the non-IBS
subjects (RR: 15.0; 95% CI: 4.5, 50.1). IBS is often con-
sidered a diagnosis of exclusion, and while we assume
that our well-defined IBS definition includes the result
of a “negative colonoscopy”, such an assumption does
not rule out potential microscopic colitis which is asso-
ciated with similar symptoms and normal endoscopic
mucosal appearance on colonoscopy and may not have
been diagnosed [26,27]. The utilization of our well-
defined IBS population may have resulted in a biased se-
lection of IBS patient types, perhaps those who had
more severe disease with underlying inflammatory/immune dysfunction not detected on colonoscopy or
histopathology or those more likely to have a diarrheal
component. In fact, in a number of patients with IBS,
the colonic mucosa appears normal; however, there are
histopathological changes in the rectum, a region not
commonly biopsied during colonoscopy for IBS symp-
toms. Furthermore, it is possible that IBS subjects may
have had IBD, specifically, Crohn’s disease, for which
small intestine mucosal abnormalities were not visua-
lized. In our data, the relative risk of CD in those with
well-defined IBS was 18.4 compared to the non-IBS
comparator group. This was slightly higher than the esti-
mates utilizing all IBS subjects (RR: 11.2) which supports
misclassification may be present. However, our findings
of increased risk for UC for which colonoscopic and/or
histopathological diagnosis are likely more sensitive, sug-
gest that in “colonoscopy negative” IBS patients there is
an increased risk of developing UC. In total, these data
suggest that IBS patients are at increased risk of IBD
and additional studies are needed to ascertain whether
certain genetic or immunologic abnormalities underlie
both of these conditions, and determine which subset of
IBS patients may be at higher IBD risk.
We found a median IBD onset time of 2.1 years (IQR:
1.4, 3.8) with no significant difference between UC and
CD (2.8 and 2.1 years, respectively). Furthermore, there
was no difference in the time to IBD onset for subjects
with no prior history of IBS (median: 2.6 years; IQR: 1.9,
4.5). In contrast, Pimentel et al. noted a prodromal
period for patients who were ultimately diagnosed with
UC or CD with a longer delay in CD patients (7.7 years)
than UC patients (1.2 years) [7]. A possible explanation
for the apparent discrepancy in prodromal periods be-
tween the two studies may be the method by which
these data were obtained or differences in healthcare
access or health-seeking behavior between study popula-
tions. While the study by Pimentel et al. used a self-
reported questionnaire of subjects after IBD onset, our
study utilized medical encounter data. Both methodolo-
gies have inherent limitations and potential sources of
bias.
We also found a 4-fold increased risk of IBD among
subjects with more than 1 documented episode of IGE
after controlling for other important covariates. Others
have reported similar associations between antecedent
IGE and IBD, [6,9,10,16]. The consistency of this finding
seems to point to a direct association, though a causal
link has not yet been established. Other covariates were
associated with differential IBD risk. Specifically, males
had a slightly higher risk of IBD than females. However,
looking at IBD subtypes, this association was only sig-
nificant with CD. In contrast, a 1999 population-based
study of IBD incidence in a Canadian province showed a
significantly higher rate of CD in women than in men,
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port on IBD incidence in participants in a specific mana-
ged care organization found similar rates of UC and CD
among men and women [28]. One possible explanation
is that the population based study did not control for
comorbid IBS, a FGD that is known to be more com-
mon in females [29]. Deployment during the study
period was associated with a decreased IBD risk. At first
glimpse, this appears contradictory to what may be
expected given that deployments are frequently to
regions at high risk of IGE, often associated with bacter-
ial pathogens linked to an increased IBD risk [9,10].
However, the likely explanation of this inverse associ-
ation is that of a healthy worker effect. As stated previ-
ously, there is a recognized prodrome for IBD. It is
reasonable to assume that subjects with such a complex
of symptoms may be less likely to be deployed due to
undiagnosed health concerns precluding one from ad-
equately performing in a deployed setting. A similar
finding has been reported with non-specific arthralgia
and arthropathy [30]. Alternatively, there may be an in-
herent delay in the diagnosis of IBD in military popula-
tions, as this and similar diagnoses can result in medical
discharge, [6] and military personnel who are motivated
to deploy may be of a type that are less likely to seek
care for chronic underlying diseases in order to avoid
diagnosis and separation.
In addition to the association between IBS and IBD,
we found an increased incidence of IGE among our IBS
cohort, compared to subjects without IBS. While the risk
of IBS following IGE, termed post-infectious IBS (PI-
IBS), has been well documented [11], to our knowledge,
this is the first report of increased IGE risk in subjects
with IBS. DuPont et al. reported a worsening of func-
tional GI symptoms following an episode of travelers’
diarrhea (TD) in subjects with IBS [31]. However, the
authors did not assess whether the risk of TD was higher
among those with IBS. We were limited in our assess-
ment of infectious gastroenteritis (IGE) to only episodes
associated with a medical encounter, and it has been
well-established that only a small proportion of IGE epi-
sodes actually seek medical care [32]. Therefore, it is
possible that the observation of an increased rate of IGE
in the IBS cohort may be related to the fact that those
subjects were more likely to seek care for an incident
IGE episode than their non-IBS counterparts. Thus, this
observation may be solely due to differences in care
seeking behavior or differences in the severity of diar-
rheal and non-diarrheal symptoms such as abdominal
pain or cramps, nausea, malaise or myalgia. In an effort
to evaluate differences in the care seeking behavior in
our 2 study populations, we analyzed the number of in-
patient and outpatient medical encounters and found
that after removing IBS- and IBD-associated visits, IBSsubjects were more likely (p< 0.001) to present for
medical care (median number of outpatient visits: 49;
IQR: 20, 89) than were the non-IBS comparator cohort
(median: 29; IQR: 14, 56). An alternative explanation is
that due to the common clinical features, IBS symptoms
may have been misdiagnosed as being of infectious eti-
ology. Unfortunately, inadequate sample collection and
microbiology is commonplace with infectious gastroenter-
itis [32], so we are unable to assess this potential bias.
The mechanism(s) by which IBS may increase one’s
susceptibility to specific pathogens are unknown; how-
ever, there are several potential possibilities. First, in
patients with IBS, there is a modification of genetic
expression and secretion of important chemokines such
as interleukin 8 (IL-8), which is decreased in those with
IBS [33]. IL-8 is also known to recruit neutrophils to the
intestinal mucosa during infection with organisms asso-
ciated with travelers’ diarrhea [34]. Another possibility is
that the modified intestinal microbiome in a subset of
IBS patients may influence subsequent IGE risk [35].
Furthermore, in a subset of IBS patients evidence of mu-
cosal barrier dysfunction is apparent which could in-
crease susceptibility to enteric infection [36-38]. Of note,
we found a significantly higher incidence of protozoal-
attributed IGE than was seen for either bacterial or
viral-associated IGE though the lack of pathogen-specific
data in this study precludes an assessment of pathogen-
specific risks. These findings need validation in a differ-
ent population, and if found to be consistent would have
certain implications on considerations regarding man-
agement of patients with IBS in situations where IGE
risk is high. Travelers from developed to developing
countries and deployed military personnel have consist-
ently high attack rates of travelers’ diarrhea [39,40]. Fur-
ther study is needed to evaluate whether certain IBS
subtypes, including PI-IBS, are at increased risk for IGE
and IBD. If the association between IBS, IGE and IBD is
found in additional studies of other populations,
increased emphasis on preventive efforts may be needed
in those subpopulations with IBS to include consider-
ation of antibiotic chemoprophylaxis as currently recom-
mend for high-risk groups [41,42].
As previously stated, there are inherent limitations to
the data presented herein and the results should be
interpreted with caution. First, the use of a medical en-
counter database is a potential source for misclassifica-
tions of exposure, outcome and other covariates due to
inaccurate ICD-9 or CPT coding. We attempted to re-
duce the impact of this misclassification by requiring
multiple medical encounters to document both the ex-
posure and outcome of interest as has been described
previously [43]. Incident IBS was defined as the first
medical encounter for which a diagnosis of IBS was
given to a case that subsequently went on to meet the
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related medical encounter as ‘new onset’ may not ac-
count for subjects with a pre-existing diagnosis of IBS
prior to his/her military service which may have artifi-
cially decreased the diagnosis time. Importantly, as part
of the military screening process, potential servicemem-
bers are screened to ensure they are in good general
health. Screening for functional bowel disorders is not
done, nor would it be exclusionary. Thus we cannot
necessarily rule out someone with pre-existing IBS; how-
ever, it does minimize the potential impact of this limita-
tion inherent in this study design. Additionally, we
analyzed a subset of subjects for which colonoscopies
had been performed in an attempt to remove potential
misclassification of our exposure of interest. Unfortu-
nately, due to a lack of specific ICD-9 codes, we were
unable to analyze IBS subtypes and their potential differ-
ential effect on IBD risk. Another limitation inherent
with these data is our inability to capture other import-
ant covariates, such as smoking and stress. We also
were unable to completely account for subjects with
pre-existing IBS, artificially decreasing the diagnosis time
from IBS to IBD. Future studies utilizing more prospect-
ive designs should evaluate the potential differential effect
these covariates may have on the reported associations.
Additionally, while we noted an increase in the relative
risk of IBD associated with IBS, the absolute risk of IBD
was low and limitations in ICD-9 codes may have con-
tributed to observed associations.
Conclusions
In summary, we found a significant increased risk of
IBD among a cohort of subjects with IBS compared to a
matched reference cohort with no prior IBS. Addition-
ally, we found that intercurrent infectious gastroenteritis
further increased this IBD risk. Future studies in other
populations using well controlled prospective study
designs are needed to verify these results, though would
be challenging due to the large numbers of subjects that
would need to be followed. However, these data reflect
the complex interaction between functional and inflam-
matory bowel disorders and implicate a common patho-
genesis and important role of infectious gastroenteritis.
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